SCHEMBL6017732

SCHEMBL6017732

CN(c1cccc(F)c1C#N)S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 5/20 0.37
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
TSHR P16473 1/20 0.34
HTT P42858 2/20 0.34
C5AR1 P21730 1/20 0.33
CYP19A1 P11511 2/20 0.33
PARP1 P09874 1/20 0.33
USP2 O75604 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21048864 0.85 ALDH1A1 (0.37) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1291338 0.82 CYP1A2 (0.40) KMT2AALDH1A1L3MBTL1TSHRHTT
SCHEMBL30986042 0.79 ALDH1A1 (0.44) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2076283 0.79 ALDH1A1 (0.44) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL26519237 0.77 KMT2A (0.50) KMT2AALDH1A1ALOX5APFEN1HSD17B10
SCHEMBL8377733 0.74 TAS1R3 (0.34) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1291364 0.73 ALDH1A1 (0.51) KMT2AALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL30468495 0.73 ALDH1A1 (0.51) KMT2AALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL15461576 0.73 EPAS1 (0.45) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL11089868 0.72 ALDH1A1 (0.56) ALDH1A1ALOX5APFEN1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS KMT2A 710/4885ALDH1A1 633/4885ALOX5AP 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.